GlassScriptPhysician profile
Carlos O Dator
NPI 1114287158
$1,977.96
in general payments reported to CMS, 2019-2025
22 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $320 · 2021: $603 · 2022: $237 · 2023: $90.04 · 2024: $236 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $341.74 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $243.43 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $196.49 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $177.11 | 2019-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $168.55 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.43 | 2020-2023 | Trulance, Xifaxan |
| Exact Sciences Corporation | $110.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Advanced Oxygen Therapy INC. | $86.85 | 2020-2021 | |
| Lundbeck LLC | $69.72 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $61.92 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $58.12 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Amarin Pharma, INC. | $55.61 | 2020-2021 | |
| Lilly USA, LLC | $49.25 | 2025 | Kisunla, Mounjaro, Zepbound |
| Pfizer INC. | $40.64 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $39.57 | 2021-2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.73 | 2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $35.33 | 2019-2022 | |
| Misonix INC | $23.39 | 2021 | |
| Abbvie INC. | $19.29 | 2022 | |
| Sumitomo Pharma America, INC. | $17.11 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.23 | 2021 | |
| Allergan, INC. | $12.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Dator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.